Clinical Trials

55 enrolled

Pancreatic Neoplasms

NCT06538207 2025-02-06

An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer

46 enrolled

Pancreatic Neoplasms

NCT03161379 2025-02-03

GVAX Pancreas Vaccine (With CY) in Combination With Nivolumab and SBRT for Patients With Borderline Resectable Pancreatic Cancer

Phase 2 Completed

31 enrolled 9 charts

Pancreatic Neoplasms

NCT04731467 2024-12-27

A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors

DermatologicEndocrineGastrointestinalGynecologicHead & NeckThoracic

79 enrolled

Thyroid Cancer, Papillary, Carcinoma, Non-Small-Cell Lung, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms

NCT02009449 2024-11-15

IVY

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

353 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT03565445 2024-11-01

A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors

BreastGastrointestinalGynecologicHead & Neck

190 enrolled

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms

NCT04098432 2024-09-23

CA209-9KH

15 enrolled

Pancreatic Neoplasms

NCT03190265 2024-08-07

Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer

Phase 2 Completed

61 enrolled 11 charts

Adenocarcinoma, Carcinoma, Neoplasms, Pancreatic Neoplasms

NCT03373188 2024-03-20

VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer

10 enrolled

Pancreatic Neoplasms, Colorectal Neoplasms

NCT04299880 2023-11-08

Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Boston Biomedical-sponsored Protocols

7 enrolled

Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Pancreatic Neoplasms

NCT03953235 2023-09-13

A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens

39 enrolled

GastrointestinalThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Colorectal Neoplasms

NCT04953962 2023-08-15

Study of CBP501/Cisplatin/Nivolumab Combinations in Advanced Pancreatic Cancer

Phase 2 Completed

36 enrolled

Pancreatic Neoplasms

NCT04050085 2023-08-01

SD-101, Nivolumab, and Radiation Therapy in Treating Patients With Chemotherapy-Refractory Metastatic Pancreatic Cancer

6 enrolled

Pancreatic Neoplasms

NCT03829436 2023-07-03

TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers

BreastGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

38 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors